PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Botulinum toxin type A - Hypersalivation in children

PAD Profile : Botulinum toxin type A - Hypersalivation in children

Keywords :
MND, acquired brain injury, neurodisability, cerebral palsy, long term ventilation, drooling, drug-induced hypersalivation, sialorrhea, botox
Brand Names Include :
Xeomin

Traffic Light Status

Status 1 of 1.

Status :
N/A
Important
Formulations :
  • Not Specified
Important Information :
Not assessed for formulary status.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
11 November 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicans can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission. 
 

Associated BNF Codes

04. Central Nervous System
04.09.03. Essential tremor,chorea,tics and related disorders
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More